Biocon Acquires All Equity of Biocon Biologics Limited, Increases Share Capital via Preferential Allotment
Biocon Limited has completed the acquisition of all equity shares in its material subsidiary, Biocon Biologics Limited (BBL). The company subsequently allotted a tranche of its own equity shares to the selling shareholders as consideration for the acquisition.The acquisition process was finalized on June 29, 2026, making BBL a wholly-owned subsidiary of Biocon Limited effective that day. During this transaction, the Company acquired 11,536,956 equity shares of BBL from 127 selling shareholders.As part of the consideration for the acquisition, Biocon issued and allotted 8,786,362 fully paid-up equity shares to the aforementioned...